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Survival and pattern of failure after postoperative radiation therapy
for medulloblastoma in adult patients
Agnieszka ˚ó∏ciak, Lucyna K´pka, Jacek Fijuth, Czes∏awa Leszczyk
A i m.  To present the results of postoperative radiotherapy in 27 adult patients with medulloblastoma and to design future ma-
nagement strategies.
M a t e r i a l  a n d  m e t h o d s.  27 patiens with medulloblastoma were treated between 1984 and 2000, of whom 26 received
craniospinal irradiation (median 33.6 Gy) with a boost to the posterior fossa (55 Gy). No patient received chemotherapy at
primary treatment. Pattern of failure, overall survival (OS), disease free survival (DFS) and survival after recurrence (SAR)
were analysed. Age, tumour location, desmoplasia in histology examination, extent of resection, shunt presence, performan-
ce and neurologic status were included in a univariate analysis in order to assess possible factors influencing overall survival.
The disease stage was disregarded because of insufficient initial staging.
Re s u l t s.  Actuarial 5- and 10- year OS rates were 55% and 44%, respectively. Actuarial 5- and 10- year DFS rates were 44%
and 31% respectively. In univariate analysis age was the only significant prognostic factor for OS. For patients less than 30 years
of age 5-year OS rate was 40%, for elders – 90%, p=0.004. A tendency to improve OS was observed with better performan-
ce and neurologic status, and location in the cerebellar hemisphere, whilst the presence of shunt and gross total resection wor-
sened OS without statistical significance.
Tumour recurred in 17 (63%) patients. Ten relapses (59%) occurred within the first 2 years of follow up. Seven recurrences we-
re in the posterior fossa, either alone (3 patients) or both in the posterior fossa and other sites (4 patients). Other relapses oc-
curred either alone or in 2 or more sites such as: the supratentorial region (3 patients), the spine (4 patients), outside the CNS
(6 patients). The median SAR was 12 months (1-35 months). Mean SAR for patients receiving chemotherapy at relapse was
19 months, whilst for patients treated without chemotherapy the mean SAR was 5 months. A tendency for longer SAR was ob-
served when recurrence occurred later after primary treatment. Mean SAR for patients relapsed after 3 years was 16 months,
whilst for patients relapsed within 3 first years it was 9.5 months.
C o n c l u s i o n s.  Results are poor, but similar to those cited in literature. Results should be related to the presence of progno-
stic factors, especially the initial extent of disease. The frequency of recurrences in the posterior fossa and outside the CNS is
similar. Accurate initial staging could differentiate patients for whom the use of chemotherapy or implementation of new ra-
diotherapy techniques is meaningful. The majority of relapses were observed within the first 2 years. Older patients have bet-
ter overall survival.
Ocena wyników i przyczyn niepowodzeƒ pooperacyjnego napromieniania
doros∏ych chorych na rdzeniaka p∏odowego
C e l. Ocena wyników pooperacyjnej radioterapii 27 doros∏ych chorych na rdzeniaka p∏odowego (medulloblastoma).
M a t e r i a ∏  i m e t o d a.  Poddano analizie 27 chorych na rdzeniaka p∏odowego, leczonych napromienianiem w II Zak∏adzie
Teleradioterapii Centrum Onkologii im. M. Sk∏odowskiej-Curie, w latach 1984-2000. Dwudziestu szeÊciu chorych napromie-
niono na oÊ mózgowo-rdzeniowà (mediana – 33,6 Gy), podwy˝szajàc dawk´ na tylny dó∏ czaszki do 55 Gy. Jeden chory by∏
napromieniony paliatywnie na mózg. Chorym nie podawano chemioterapii jako pierwotnego leczenia. Przeprowadzono
analiz´ niepowodzeƒ leczenia, prze˝ycia ca∏kowitego, prze˝ycia bez nawrotu choroby i prze˝ycia po wznowie (PPW). Oceny
czynników rokowniczych dokonano w analizie jednowymiarowej, w∏àczajàc wiek, stan ogólny, stan neurologiczny, zakres re-
sekcji, lokalizacj´ guza (robak versus pó∏kula mó˝d˝ku), obecnoÊç desmoplazji i obecnoÊç zastawki w komorze mózgu. Do
analizy nie w∏àczono stopnia zaawansowania ze wzgl´du na brak wykonywania wszystkich obowiàzujàcych badaƒ wyjÊciowych
(rezonans rdzenia kr´gowego i punkcja l´dêwiowa).
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Introduction
Modulloblastoma, as an infratentorial primitive neuroec-
todermal tumour, remains one of the most intriguing dise-
ases studied and treated by the multidisciplinary oncology
team because of its unique characteristics and apparent ra-
diocurability. This tumour occurs most commonly in chil-
dren, very rarely in adults. Standard therapy consists of
maximal resection compatible with good neurologic outco-
me and postoperative craniospinal irradiation (CSI) with
a boost to the posterior fossa using conventional fractiona-
tion schemes. The role of chemotherapy is still debated.
The main aim of this study is to present the results of
postoperative radiotherapy in 27 patients with medullo-
blastoma treated at the 2nd Department of Radiation
Oncology of The M. Sklodowska-Curie Memorial Cancer
Center (MSCMCC) and Institute of Oncology in War-
saw. The second aim is to design future management
strategies basing upon our own experiences and publi-
shed data.
Materials and methods
The records of 27 patients referred for radiotherapy to the 2nd
Department of Radiation Oncology of the MSCMCC between
January 1984 and June 2000 were reviewed.
There were 22 male and 5 female patients, mean age – 28
yrs. The most common presenting symptoms were headache,
gait imbalance, nausea, vomiting, ataxia, dysmetria, nystagmus,
and cranial nerve dysfunction. Performance status evaluated ac-
cording to WHO score was 0 in 2 patients, I in 18, II in 3 and III
in 4 patients. Neurologic status evaluated according to the
EORTC\MRC score (Table I) [1] was I in 15 patients, II in 8 pa-
tients, and III in 4. All patients had histopathologic diagnosis of
medulloblastoma. Desmoplasia was present in 5 cases.
The tumour was located in the vermis in 7 patients, in the
vermis and 4th ventricle in 6 pts. Seven pts. had infiltration limi-
ted to the cerebellar hemispheres. In 4 cases the tumour invaded
both the vermis and the cerebellar hemisphere. Two tumours
were located in the cerebellopontine angle. One patient had
a midline lesion that extended into the brainstem. Tumour size
was not routinely recorded.
The mean interval from operation to onset of radiotherapy
was 39 days (range: 20-82 days).
The extent of resection was mainly based on the surge-
on's assessment at the time of the operation. Two patients under-
went partial resection, 9 – a subtotal resection and 16 – a gross
total resection.
Seven patients required a shunt before radiation therapy,
one shunt was placed during radiotherapy because of hydroce-
phalus.
In this retrospective material no patient had undergone
complete staging before treatment, incl. no MRI of the spine and
no CSF samples for cytological analysis. None of the patients we-
re found to have metastases (in view of such incomplete dia-
gnosis).
All patients received radiation therapy. The median dose
given to the posterior fossa was 55.0 Gy (range: 30.0-60.8 Gy),
and 33.6 Gy to the craniospinal fields (range: 26.4-40.0 Gy).
One patient was treated with palliative intent, without spinal
irradiation. For all but two patients receiving hyperfractiona-
ted CSI to 30 Gy with 1.2 Gy per fraction twice a day, doses
per fraction were 1.6-2.0 Gy (median:1.8).
High-energy photons (Co60, X6 and X15 MV) and elec-
trons (15 to 22 MeV) were employed. A three dimensional tre-
atment planning system was used for 4 patients only – treated
after 1996.
The average duration of the treatment course was 70 days
(range: 12-124 days).
W y n i k i.  Prze˝ycie 5- i 10-letnie wynios∏o odpowiednio 55 oraz 44%. Prawdopodobieƒstwo 5- i 10-letniego prze˝ycia bez na-
wrotu choroby wynosi∏o odpowiednio 44 i 31%. Wiek okaza∏ si´ jedynym istotnym czynnikiem prognostycznym w analizie jed-
nowymiarowej. Pi´cioletnie prze˝ycie ca∏kowite dla chorych w wieku poni˝ej 30 lat wynosi∏o 40%, a dla chorych w wieku 30
i wi´cej lat 90% (p=0,004). Obserwowano tendencj´ do poprawy prze˝ycia chorych w dobrym stanie ogólnym i neurologicz-
nym, z lokalizacjà guza w pó∏kuli mó˝d˝ku, natomiast obecnoÊç zastawki i radykalizm operacji pogarsza∏y prze˝ycie (bez zna-
miennoÊci statystycznej).
U 17 chorych stwierdzono wznow´. 10 wznów (59%) wystàpi∏o w ciàgu pierwszych 2 lat obserwacji. Stwierdzono 7 niepowo-
dzeƒ leczenia w zakresie tylnego do∏u czaszki, jako jedyne miejsce (3) lub z towarzyszàcymi przerzutami (4). Niepowodzenia
odleg∏e wystàpi∏y w jednej lub wielu lokalizacjach: nadnamiotowo (3), rdzeƒ kr´gowy (4), poza CSN (6). Mediana PPW wy-
nosi∏a 12 miesi´cy (przedzia∏: 1-35 miesi´cy). Ârednia PPW chorych leczonych chemicznie z tego powodu wynios∏a 19 miesi´-
cy, a chorych nie leczonych cytostatykami – 5 miesi´cy. Obserwowano tendencj´ do d∏u˝szego PPW, im wznowa pojawia∏a si´
póêniej od pierwotnego leczenia. Gdy wznow´ stwierdzano w ciàgu pierwszych 3 lat obserwacji, Êrednie PPW wynosi∏o 9.5 mie-
siàca, a w przypadkach, gdy wznow´ stwierdzono póêniej, Êrednie PPW wynosi∏o 16 miesi´cy.
W n i o s k i.  Wyniki pooperacyjnego napromieniania chorych na rdzeniaka p∏odowego sà niezadowalajàce. Ich ocen´
utrudnia brak wyjÊciowego zaawansowania choroby. Cz´stoÊç niepowodzeƒ miejscowych i odleg∏ych jest podobna. Do
wi´kszoÊci nawrotów dochodzi w pierwszych 2 latach obserwacji. Starsi chorzy majà lepsze rokowanie.
Key words: medulloblastoma, radiotherapy
S∏owa kluczowe: rdzeniak p∏odowy
Table I. EORTC/MRC Neurologic Deficits Score [1]
1. Absence of any neurologic deficit detectable
2. Minor neurologic deficits; without any impairment of normal activity
3. Neurologic deficits leading to some impairment of normal activity (paresis, minor mental changes)
4. Serious neurologic deficits leading to disability to care for himself: paralysis, aphasia, serious mental (emotional and/or cognitive) changes
5. Any communication with patient impossible
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None of the patients received chemotherapy at primary
treatment. One patient received lomustine (CCNU) during the
last week of radiotherapy, because of a suspicion of bone meta-
stases, not confirmed by complementary examination carried
out at the end of the treatment. Nine patients received chemo-
therapy at recurrence.
Overall survival (OS) and disease free survival (DFS), me-
asured from the onset of radiotherapy, were calculated using
the Kaplan-Meier method.
Univariate analysis (UA) using the log rank test was perfor-
med in order to assess possible prognostic factors for OS. The
following factors were included in the UA: age, extent of resec-
tion, performance status, neurologic status, tumour location
(vermis vs cerebellar hemisphere), desmoplasia in histology exa-
mination and shunt presence.
Results
Mean follow up was 60.7 months (range: 5-204 months).
Minimum follow-up for alive patients was 17 months.
The tolerance of radiotherapy was good. Only mode-
rate early complications (erythema, alopecia, leukopo-
enia at 2000-3000 (11 pts.), mild diarrhoea (2 pts.)) were
observed. One patient developed hydrocephalus and rece-
ived the planned dose after shunting. Eighteen patients
received corticoids during radiotherapy. No severe late
complications were observed in the studied group.
No patients developed secondary malignancies.
Actuarial 5- and 10- year OS rates were 55% and
44%, respectively (Figure 1). Actuarial 5- and 10- year
DFS rates were 44% and 31% respectively (Figure 2).
Twelve patients died.
In the univariate analysis age was the only signifi-
cant prognostic factor for OS. For patients younger than
30 years (17 cases) and with age ≥30 years (10 cases) 5-
-year OS rates differed significantly (40% and 90% re-
spectively, p=0.004) (Figure 3). We observed a trend to-
wards improved OS with better performance and neuro-
logic status and location in the cerebellar hemisphere,
whilst the presence of shunt and gross total resection
worsened OS without statistical significance. Table II
shows results of UA for all analysed variables.
Table II. Prognostic factors for overall survival in univariate analysis
Variable 5-year survival P-value in log 
rank test
Age:
< 30 years 32% 0.004
≥30 years 90%
Extent of resection
Gross total resection 48% 0.58
Subtotal, partial and biopsies 67%
Performance status
0-I 58% 0.20
II-III 43%
Neurologic status
I 60% 0.25
II-IV 47%
Location
Cerebellar hemisphere 64% 0.41
Vermis 48%
Shunt
Present 31% 0.17
Absent 65%
Desmoplasia
Present 53% 0.81
Absent 55%
The multivariate analysis was not performed becau-
se of a limited number of patients.
Figure 1. Overall survival of 27 patients with medulloblastoma estima-
ted by the Kaplan-Meier method
Figure 2. Disease free survival of 27 patients with medulloblastoma es-
timated by the Kaplan-Meier method
Figure 3. Overall survival of 27 patients with medulloblastoma accor-
ding to age (p=0.004)
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17 (63%) patients recurred. Ten relapses (59%) oc-
curred within the first 2 years of follow-up, 2 (11.7%) be-
tween 3 and 4 years, 3 (17.5%) between 4 and 5 years, 1
(5.9%) after 5 years, and 1 (5.9%) after 11 years. Seven
recurrences were found in the posterior fossa, either alo-
ne (3 pts.) or in both posterior fossa and other sites (4
pts.). Metastatic relapses occurred either alone or in 2
or more sites, such as the supratentorial region (3 pts.),
the spine (4 pts.) or outside the CNS (6 pts.). In 5 cases
there was insufficient staging to localise the recurrence.
Recurrences outside the CNS were located in bones (6
pts.), lymph nodes (1 pts.) and lung (1 pts.). One supra-
tentorial relapse was due to a geographic miss by excess
blocking of the orbital region.
The median survival after recurrence (SAR) was 12
months (range: 1 – 35 months). Treatment for recurrence
included surgery in 3 patients, while radiation therapy
was given to 6 patients, including radiosurgery for one.
Eight patients were treated by chemotherapy – this was
associated with longer SAR. Mean SAR for patients rece-
iving chemotherapy at relapse was 19 months (range: 7-34
months), whilst for patients treated without chemothera-
py the mean SAR was 5 months (range 1-17 months).
A tendency towards longer SAR was also observed when
the recurrence occurred later after primary treatment.
Mean SAR for patients relapsed after 3 years was 16
months, whilst for patients relapsed within 3 first years the
mean SAR was 9.5 months.
Discussion
Our results concerning the survival of 27 patients with
medulloblastoma are similar to the outcomes reported
by other authors, ranging from 52% to 68% at 5 years
and from 25% to 64% at 10 years [2-12].
The main problem in the evaluation of results in our
study is related to an unknown distribution of progno-
stic factors caused by insufficient staging. As is stated in li-
terature the extent of the disease is significantly associated
with the length of survival. Early failures are attributed to
poor prognosis – "high risk" patients being primarily cha-
racterised by the presence of leptomeningeal metastases
(M1-4 stage) (Table III) [13]. Other poor prognostic fac-
tors include partial resection of the tumour, age below 3
years and brainstem invasion [2-5].
The dose delivered to the neuraxis and the poste-
rior fossa is a crucial problem. In this study patients were
fractionated conventionally to median dose of 55 Gy to
the posterior fossa and 32 Gy to the spine. The total and
fractional doses were delivered acc. to literature recom-
mendation. Contemporary protocols recommend 36 Gy
to the craniospinal axis and 54-56 Gy to the posterior
fossa, 1.8-2 Gy per fraction, using 3-dimensional treat-
ment planning system.
Reduced dose neuraxis irradiation (23.4 Gy vs. 36
Gy) is associated with an increased risk of relapse [14].
Survival did correlate with the dose to the cranial field
with threshold dose of 30 Gy [15]. The results are also
worse when the dose given to the posterior fossa is less
than 50 Gy, however higher doses (72 Gy, 1 Gy twice da-
ily) did not improve survival [9, 16-18].
Leptomeningeal failure is a common component of
failure and occurs in the posterior fossa, as well as in the
spine. Posterior fossa recurrence (as a component of failu-
re) occurs in 55-71% [2, 3, 5]. Seven patients (58% of
known locations of failures) in our study relapsed in the
posterior fossa. Isolated tumour bed failure occurred in 3
(25%) cases, others report 22% -50% [2, 3, 5]. The spine
was affected in 4 (33%) cases, as compared to 20%-38%
in literature [2, 5, 9]. Isolated supratentorial recurrence is
a rarely observed event (12%) and is commonly caused by
an inadequate dose to the region of the cribriform plate
[9]. Among 3 relapses diagnosed in this region, observed
in our study, there was one relapse caused by geographic
miss. It is important to properly cover the subfrontal cri-
briform plate region by an elective dose, and avoid exces-
sively generous eye blocks. The quality of medullobla-
stoma radiotherapy technique definitely correlates with
the outcome.
It is worth to consider some issues in the technical
conduct of CSI for medulloblastoma. There is a need to
change the spinal-spinal and cranial-spinal junction every
10 Gy, while to determine the inferior margin of the field
the saggital MRI images should be used for proper loca-
tion of the caudal sac. Treatment plan includes irradiation
of the entire subarachnoid space extending to the spinal
ganglia located in the intervertebral foramina. The entire
posterior fossa should be exposed to the full dose [19].
The preferred cranio-spinal junction is at the lowest point
in the neck with exclusion of the shoulders in the lateral
cranial field, which results in a higher dose to the cervical
Table III. Chang Harisiadis classification system for cerebellar medulloblastoma [13]
T1 <3 cm in greatest dimension
T2 ≥3 cm
T3a ≥3 cm with extension into the aqueduct of Sylvius and\or into foramen of Luschka
T3b ≥3 cm with unequivocal extension into the brainstem
T4 ≥3 cm with extension up past the aqueduct of Sylvius and\or down past the foramen magnum
M0 No evidence of subarachnoid or hematogenous metastasis
M1 Microscopic tumour cells found in cerebrospinal fluid
M2 Gross nodular seeding demonstrated in the cerebellar or cerebral subarachnoid space, or in the 3rd or
lateral ventricles
M3 Gross nodular seeding in spinal subarachnoid space
M4 Metastasis outside the cerebrospinal axis
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spinal cord, but the doses received by the thyroid gland,
mandible, pharynx and larynx are lower [20].
There is a consensus that prolonged treatment time
influences the results. John O. Charco et al. [10] have
demonstrated that for patients with radiotherapy duration
less than 45 days the posterior fossa control was 89% at 5
years, as compared with 68% for those treated longer
(p=0.01). Similarly freedom from relapse at 5 years was
76% and 43%, respectively (p=0.04).
The average duration of irradiation in our group of
patients was 70 days. That is so because before 1996 bra-
in and spine irradiation was performed in two stages suc-
cessively. Without appropriate initial staging we cannot
conclude to what extent this worsened the results.
Interpretation of the univariate analysis concerning
prognostic factors is also strongly compromised by the
absence of data concerning the initial extent of the dise-
ase. Additionally, the size of the group is small – a com-
mon problem in one-centre studies on adult medullobla-
stoma. Christian Carrie et al. [12] identify postoperative
performance status as a prognostic factor. Complete re-
section is of no benefit if it results in poor postoperative
performance status. It may be the reason of our surprising
results with no significant worsening of survival with larger
tumour resection.
Some authors claim that the presence of desmoplasia
in tumour is a positive prognostic factor and the presence
of a shunt is a negative prognostic factor [2, 3, 6, 7]. We
did not arrive at this relation, maybe because of a small
number of events.
There is a very interesting rule, referred to as Co-
lin's law, which can be of help to estimate the chance of
cancer cure in children and young adults. It is also appli-
cable to medulloblastoma patients. The cure could be as-
sured if patients survived their age and 9 months beyond
diagnosis [21]. Patients with later recurrence had a longer
SAR. Additionally, medulloblastoma occurring in older
patient is slightly less aggressive. There was longer survi-
val among older patients. Medulloblastoma is an exceptio-
nal brain neoplasm where older age of the patient does
not worsen survival [4].
Benefits of chemotherapy are still controversial, as
most studies are not conclusive. Results of surgery and ra-
diotherapy can be improved by the positive impact of
chemotherapy in decreasing the risk of extraneural meta-
stases by the use of chemotherapy in more advanced cases
[2]. Good results have been reported using cisplatinum in
the "high risk" population and using the 8/1 (VCR,
BCNU, procarbazine, Hydrea, cisplatinum, aracytin C,
cyclophamine) regimen in the M7 protocol [12]. In M0
patients receiving chemotherapy before CSI, the risk of
neuraxis progression seems to increase with the duration
of chemotherapy [11]. Many institutions prefer to use of
chemotherapy after CSI or at recurrence, only because ra-
diotherapy is a "gold standard" and it is risky to delay the
onset of proper treatment, especially in adults. There was
an observed benefit of treating recurrences with chemo-
therapy in this study. This statement has limitations be-
cause of a retrospective character of the study. When re-
currence is less aggressive, there appears a chance to co-
nvey the treatment.
New approaches of treating medulloblastoma are
being investigated, including dose escalation with stereo-
tactic or conformal techniques, either as primary treat-
ment or at relapse. Radiosurgery appears to reduce the
proportion of first failures occurring locally when it is as
a part of initial management [22].
To summarise, accurate staging is necessary to iden-
tify all sites of disease and to assess the risk of recurrence,
allowing appropriate decisions concerning therapy. In
"high risk" patients the results of surgery and radiothera-
py can be improved by chemotherapy, especially decre-
asing the risk of extraneural metastases [2]. A study con-
cerning the implementation of new radiotherapy methods
could be also carried out for patients with increased risk
of local failure.
It is tempting to speculate that improvements in ima-
ging and treatment may alter the results.
Conclusions
1. Reported results of conventional postoperative radio-
therapy for medulloblastoma patients are poor, but
similar as stated in literature.
2. All treatment results for medulloblastoma patients
should be related to the presence of prognostic fac-
tors, especially to the initial extent of the disease.
3. The frequency of recurrences in the posterior fossa
and outside the CNS is similar. Accurate initial sta-
ging could differentiate patients, in whom the use of
chemotherapy or implementation of new radiotherapy
techniques is meaningful.
4. Most of the relapses were observed within the first 2
years, but observation of late recurrences requires
a long follow-up period.
5. Older patients show better overall survival.
Agnieszka ˚ó∏ciak M.D.
2nd Department of Radiation Oncology
The M. Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology
ul. Roentgena 5
02-781 Warsaw
Poland
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